Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy
{"title":"药物相关问题患者紧急重访评分的发展","authors":"Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy","doi":"10.1177/87551225211011731","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Drug-related problems (DRPs) are a frequent reason for emergency departments (EDs) visits. However, data about the risk factors associated with EDs revisits are limited. <b>Objective:</b> To develop and validate a predictive model indicating the risk factors associated with EDs revisit within 30 days of the first visit. <b>Methods:</b> A retrospective cohort study was conducted involving patients who attended an ED for DRPs related to cardiovascular drugs. A 30-day prediction model was created in a derivation cohort by logistic regression. An integer score proportional to the regression coefficient was assigned to the variables with <i>P</i> < .100 in the multivariate analysis. <b>Results:</b> 581 patients (mean age: 80.0 [12.6] years) were included, 133 (22.9%) revisited the ED within 30 days from discharge. Six factors (chronic kidney disease, chronic heart failure, visit to an ED in the preceding 3 months, high anticholinergic burden, DRPs associated with heparin, and safety-related DRPs) were identified as risk factors and combined into a final score, termed the DREAMER score. The model reached an area under the receiver operating curve values of 0.72 (95% confidence interval [CI] = 0.67-0.77) in the referral cohort and 0.71 (95% CI = 0.65-0.74) in the validation cohort (<i>P</i> = .273). Three risk categories were generated, with the following scores and estimated risks: low risk (0-8 points): 11.6%; intermediate risk (9-14 points): 21.3%; and high risk (>14 points): 41.2%. <b>Conclusion and Relevance:</b> The DREAMER score identifies patients at high risk for ED revisit within 30 days from the first visit for a DRPs, being a useful tool to prioritize interventions on discharge.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"171-177"},"PeriodicalIF":1.1000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211011731","citationCount":"0","resultStr":"{\"title\":\"Development of an Emergency Revisit Score for Patients With Drug-Related Problems.\",\"authors\":\"Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy\",\"doi\":\"10.1177/87551225211011731\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Drug-related problems (DRPs) are a frequent reason for emergency departments (EDs) visits. However, data about the risk factors associated with EDs revisits are limited. <b>Objective:</b> To develop and validate a predictive model indicating the risk factors associated with EDs revisit within 30 days of the first visit. <b>Methods:</b> A retrospective cohort study was conducted involving patients who attended an ED for DRPs related to cardiovascular drugs. A 30-day prediction model was created in a derivation cohort by logistic regression. An integer score proportional to the regression coefficient was assigned to the variables with <i>P</i> < .100 in the multivariate analysis. <b>Results:</b> 581 patients (mean age: 80.0 [12.6] years) were included, 133 (22.9%) revisited the ED within 30 days from discharge. Six factors (chronic kidney disease, chronic heart failure, visit to an ED in the preceding 3 months, high anticholinergic burden, DRPs associated with heparin, and safety-related DRPs) were identified as risk factors and combined into a final score, termed the DREAMER score. The model reached an area under the receiver operating curve values of 0.72 (95% confidence interval [CI] = 0.67-0.77) in the referral cohort and 0.71 (95% CI = 0.65-0.74) in the validation cohort (<i>P</i> = .273). Three risk categories were generated, with the following scores and estimated risks: low risk (0-8 points): 11.6%; intermediate risk (9-14 points): 21.3%; and high risk (>14 points): 41.2%. <b>Conclusion and Relevance:</b> The DREAMER score identifies patients at high risk for ED revisit within 30 days from the first visit for a DRPs, being a useful tool to prioritize interventions on discharge.</p>\",\"PeriodicalId\":16796,\"journal\":{\"name\":\"Journal of Pharmacy Technology\",\"volume\":\"37 4\",\"pages\":\"171-177\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2021-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/87551225211011731\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/87551225211011731\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/4/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225211011731","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:药物相关问题(DRPs)是急诊科(EDs)就诊的常见原因。然而,与急诊科复诊相关的风险因素数据有限。目的:建立并验证一个预测模型,表明首次就诊后30天内急诊科重访的相关危险因素。方法:对因心血管药物相关DRPs就诊的患者进行回顾性队列研究。通过logistic回归在衍生队列中建立30天预测模型。结果:纳入581例患者(平均年龄:80.0[12.6]岁),133例(22.9%)在出院后30天内再次就诊。6个因素(慢性肾脏疾病、慢性心力衰竭、前3个月急诊科就诊、高抗胆碱能负荷、与肝素相关的DRPs和安全性相关的DRPs)被确定为危险因素,并合并为最终评分,称为dream评分。模型在转诊组和验证组的受试者工作曲线下的面积分别为0.72(95%可信区间[CI] = 0.67-0.77)和0.71 (95% CI = 0.65-0.74) (P = 0.273)。产生了三个风险类别,其评分和估计风险如下:低风险(0-8分):11.6%;中度风险(9-14分):21.3%;高风险(>14分):41.2%。结论和意义:dream评分可识别DRPs首次就诊后30天内ED重访的高危患者,是优先考虑出院干预措施的有用工具。
Development of an Emergency Revisit Score for Patients With Drug-Related Problems.
Background: Drug-related problems (DRPs) are a frequent reason for emergency departments (EDs) visits. However, data about the risk factors associated with EDs revisits are limited. Objective: To develop and validate a predictive model indicating the risk factors associated with EDs revisit within 30 days of the first visit. Methods: A retrospective cohort study was conducted involving patients who attended an ED for DRPs related to cardiovascular drugs. A 30-day prediction model was created in a derivation cohort by logistic regression. An integer score proportional to the regression coefficient was assigned to the variables with P < .100 in the multivariate analysis. Results: 581 patients (mean age: 80.0 [12.6] years) were included, 133 (22.9%) revisited the ED within 30 days from discharge. Six factors (chronic kidney disease, chronic heart failure, visit to an ED in the preceding 3 months, high anticholinergic burden, DRPs associated with heparin, and safety-related DRPs) were identified as risk factors and combined into a final score, termed the DREAMER score. The model reached an area under the receiver operating curve values of 0.72 (95% confidence interval [CI] = 0.67-0.77) in the referral cohort and 0.71 (95% CI = 0.65-0.74) in the validation cohort (P = .273). Three risk categories were generated, with the following scores and estimated risks: low risk (0-8 points): 11.6%; intermediate risk (9-14 points): 21.3%; and high risk (>14 points): 41.2%. Conclusion and Relevance: The DREAMER score identifies patients at high risk for ED revisit within 30 days from the first visit for a DRPs, being a useful tool to prioritize interventions on discharge.
期刊介绍:
For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.